| Literature DB >> 35193669 |
Zohreh Ghalavand1, Masoud Alebouyeh2, Mehrzad Sadredinamin3, Mahdi Shabani4, Abdollah Karimi5, Mohammad-Reza Sohrabi6, Mohammadmahdi Karimi-Yazdi7.
Abstract
BACKGROUND: Shigellosis is a self-limiting disease that antibiotic therapy could decrease its complications and duration. However, sublethal levels of antibiotics, may lead to alteration in disease state, besides its role in the emergence of resistant variants. To understand this link, we investigated diversity of Shigella serogroups in children with diarrhea, diversity of S. flexneri serotypes, cytotoxic potential, resistance patterns to antibiotics, and alteration in transcriptional expression of main virulence genes in response to sub-inhibitory concentrations of azithromycin and ciprofloxacin.Entities:
Keywords: Drug resistance; Gene expression profiling; Serotypes; Shigella spp.; Sub-minimum inhibitory concentration; Virulence factors
Year: 2022 PMID: 35193669 PMCID: PMC8864791 DOI: 10.1186/s13099-022-00483-3
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Fig. 1Multiplex PCR products of S. flexneri clinical strains. lane 1, S. flexneri serotype 3a; lane 4 S. flexneri serotype 2a, lanes 2, 5 and 6, S. flexneri serotype 1b; lane 3, Molecular size markers (100-bp DNA ladder; SinaClon); lane 4, S. flexneri serotype 2a; lane 7, Negative control.; lane 8, S. flexneri serotype 6c
Distribution of serotypes among 97 S. flexneri isolates by multiplex PCR
| Serotype | No | Gene loci | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1b | 32 | + | + | − | − | − | − | − | + | − |
| 1c | 8 | + | + | + | − | − | − | − | − | − |
| 2a | 16 | + | − | − | + | − | − | − | − | − |
| 2b | 34 | + | − | − | + | − | − | + | − | − |
| 3a | 1 | + | − | − | − | − | − | + | + | − |
| 3b | 1 | + | − | − | − | − | − | − | + | − |
| 4a | 2 | + | − | − | − | + | − | − | − | − |
| 6 | 1 | − | − | − | − | − | − | − | − | + |
| X or Xv | 1 | + | − | − | − | − | − | + | − | − |
| Y | 1 | + | − | − | − | − | − | − | − | − |
Data are shown based on presence ( +) or absence (−) of the relevant genes as described by Sun et al. [4]
Correlation between predominant serotypes of S. flexnari and age of patients
| Serotype | Age of patients Na (%) | |||
|---|---|---|---|---|
| ≤ 5 years | 6–10 years | 11–14 years | ||
| 1b | 23 (71.9) | 7 (21.9) | 2 (6.3) | 0.037 |
| 1c | 2 (25) | 4 (50) | 2 (25) | |
| 2a | 10 (62.5) | 6 (37.5) | 0 (0) | |
| 2b | 14 (41.2) | 13 (38.2) | 7 (20.6) | |
a N (%), Number and percentage of S. flexneri serotypes in different age groups
PCR and real-time PCR primers used in this study
| Target gene | Primer sequence (5' -3') | Product size (bp) | Accession number | References |
|---|---|---|---|---|
F: CACTTGTTGGGTATGCTGG R: CCGGCAAACAGATTAGAAA | 782 | MN106906 | [ | |
F: CTGTTAGGTGATGATGGCTTAG R: ATTGAACGCCTCCTTGCTATGC | 1122 | MN106907 | [ | |
F: AGGGAATGGCATTAGGGATCGG R: GCTGCAAGTGGTTTTTGTTGGA | 518 | MN106908 | [ | |
F: ATTTATTGTTATTGGGGGTGGTTG R: ATTTGTTCTTTATTTGCTGGTT | 1272 | MN106909 | [ | |
F: ATGTTCCTCCTTCTTCCTTT R: TCCTGATGCTACCTTATCCA | 378 | MN099048 | [ | |
F: AATACGATTCTCCTGGTGCTAAAC R: TAGGGCATTGCTTGTATCTTTCAT | 905 | – | [ | |
F: AATGCTGGATGGGATAATCACCTT R: GAGACGGCTTCTCCATGTTTTGCT | 425 | MN106910 | [ | |
F: CTGTTCGGCTTTGAAAGTGCTG R: CGTAGGCGTACATAGCAAGCAAAGA | 604 | MN106911 | [ | |
F: TTAAGAGCGATCATTTC R: CCATCCAAGCGGACATT | 739 | MN919548 | [ | |
F: AACGTCAATGAGCAAAGGTATTAA R: TACGGGAGGCAGCAGTGG | 140 | – | [ | |
F: GGAAGGGAGATTGATGGTAG R: GAACTTCAAGATCTGCTCCTGC | 84 | – | [ | |
F: CTGCATTTTCAAACACAGC R: GAGTAACACTGGCAAGTC | 78 | – | [ | |
F: CTTTCGGGTACTCAAGAAC R: GAGAAAGTCCATCAACAGG | 76 | – | [ | |
F: CTCAATTCAACACTCTTTCACAG R: GCTGTACCGATGCCATGAAAAC | 82 | – | [ (This study) |
bp, base pair; F, forward primer; R, reverse primer
Antimicrobial susceptibility of S. flexneri clinical isolates
| Antimicrobial agents | ||||
|---|---|---|---|---|
| S | I | SDD | R | |
| Penicillins | ||||
| Ampicillin | 1 (1%) | 0 (0%) | – | 96 (99%) |
| Cephems | ||||
| Cefotaxime | 49 (50.5%) | 2 (2.1%) | – | 46 (47.4%) |
| Cefepime | 55 (56.7) | – | 9 (9.3%) | 33 (34%) |
| Folate pathway antagonists | ||||
| Trimethoprim-sulfamethoxazole | 5 (5.2%) | 5 (5.2%) | – | 87 (89.7%) |
| Macrolides | ||||
| Azithromycin | 87 (89.7%) | 1 (1%) | – | 9 (%9.3) |
| Quinolones and fluoroquinolones | ||||
| Ciprofloxacin | 87 (89.7%) | 3 (3.1%) | – | 7 (7.2%) |
| Nalidixic acid | 46 (47.4%) | 21 (21.6%) | – | 30 (30.9%) |
| Tetracyclines | ||||
| Minocycline | 51 (52.6%) | 18 (18.6%) | – | 28 (28.9%) |
Antimicrobial susceptibility test evaluated for antibiotics using Kirby–Bauer disk
Diffusion method (S, sensitive; SDD, susceptible, dose dependent; I, intermediate; R, resistant)
Frequency and pattern of multidrug resistance phenotype among S. flexneri isolates in children with community acquired diarrhea
| MDR phenotypes | Serotype 1b | Serotype 2a | Serotype 2b | Serotype 3a | Seroytpe 4a | Seroytpe X or Xv |
|---|---|---|---|---|---|---|
| No. (%), n = 32 | No. (%), n = 16 | No. (%), n = 34 | No. (%), n = 1 | No. (%), n = 2 | No. (%), n = 1 | |
| AMP/SXT/CIP/MN/NA | 0 | 3 (30C)a | 0 | 0 | 0 | 0 |
| AMP/CTX/CPM/SXT/MN/NA | 2 | 0 | 2 | 0 | 0 | 1 |
| AMP/CTX/SXT/MN/NA/AZM | 0 | 0 | 0 | 0 | 1 (19A)a | 0 |
| AMP/CTX/ SXT/CIP/NA | 0 | 0 | 0 | 1 (3C)a | 0 | 0 |
| AMP/CTX/CPM/SXT/MN | 1 | 0 | 3 | 0 | 0 | 0 |
| AMP/CTX/SXT/MN | 1 | 0 | 0 | 0 | 0 | 0 |
Multidrug-resistant (MDR) isolates are defined as those resistant to ≥ 3 classes among the third generation of cephalosporins, trimethoprim sulfamethoxazole, tetracycline, fluoroquinolones or macrolides
MDR, multidrug resistance; AMP, ampicillin; AZM, azithromycin; CPM, cefepime; CIP, ciprofloxacin; CTX, cefotaxime; MN, minocycline; NA, nalidixic acid; SXT, trimethoprim-sulfamethoxazole.
a.S. flexneri isolates 19A, 3C, and 30C with related MDR patterns were used for gene expression analysis
The MIC results of MDR isolates of S. flexneri to azithromycin and ciprofloxacin
| Antimicrobial agents | MICa, µg/mLa | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azithromycin (0.25–128) | Ciprofloxacin (0.125–32) | ||||||||||||||||
| 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | |
| N (%) | 1 (6.66) | 2 (13.33) | 9 (60) | 2 (13.33) | – | – | – | 1 (6.66) | – | 1 (6.66) | 10 (66.6) | – | – | – | 4 (26.6) | – | – |
| MIC50 | 2 | 0.5 | |||||||||||||||
| MIC90 | 4 | 8 | |||||||||||||||
a Minimum inhibitory concentration
N (%), number and percentage of S. flexneri isolates with different MIC values
Fig. 2Viability of S. flexneri serotypes in the absence or presence of azithromycin and ciprofloxacin. Viability rates in HT-29 cells infected with different S. flexneri serotypes in the absence or presence of azithromycin (Azt, 32 µg/mL) (A) and ciprofloxacin (Cip, 4 µg/mL) (B) during 4 h. All the assays were done in duplicate. Data are expressed as the mean of replicates ± standard deviation of mean (std)
Fig. 3The ability for interaction of S. flexneri serotypes in the absence or presence of azithromycin and ciprofloxacin. The ability for interaction of S. flexneri serotypes was measured in the absence or presence of azithromycin (Azt, 32 µg/mL) (A) and ciprofloxacin (Cip, 4 µg/mL) (B) during 30 min. Data are expressed as mean of colony forming units (cfu)/cell ± std of HT-29 cell line (10 Cells/well) from two independent experiments. Confluent cells in duplicate wells were inoculated with fresh cultures of S. flexneri strains at MOI of 100 (107 cfu). The interaction rate for each assay was calculated based on number of grown colonies from cell lysates (CFU) on Muller Hinton Agar plates per each cell in tissue culture plates after treatment time
Fig. 4Diversity in transcriptional profiles of S. flexneri virulence genes in response to sublethal concentrations of antibiotics. Transcriptional profiles of invasion plasmid antigen (ipa) B, intracellular movement (ics) A, virulence factor production (vir) B and intracellular movement (ics) B genes of S. flexneri serotypes 4a, 3a and 2a after treatment with sub-MIC concentration of A azithromycin (32 µg/mL) or B ciprofloxacin (4 µg/mL) in HT-29 cell line. Expression levels of all genes were normalized to the levels of 16S rRNA gene transcripts, and the folds of expression change were calculated using the relative comparison method (2−ΔΔct, RQ). Results shown are the mean ± std of two independent experiments
Alteration of gene expression in virulence genes of S. flexneri serotypes 4a, 3a and 2a
| Studied antibiotic classes | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| RQ values (t1–t4) | |||||||||
| t1 | t4 | t1 | t4 | t1 | t4 | t1 | t4 | ||
| 4a | Azithromycin | 0.6285 ± 1 | 0.2526 ± 0.3 | 0.6736 ± 0.08 | 0.3686 ± 0.1 | 0.5864 ± 0.1 | 2.1214 ± 1.9 | 3.4462 ± 16 | 0.1005 ± 0.3 |
| 3a | Ciprofloxacin | 21.112 ± 14.95 | 0.0103 ± 0.001 | 1.2527 ± 0.9 | 3.1167 ± 1.5 | 1.6472 ± 0.6 | 4.2575 ± 2.1 | 1.6472 ± 0.6 | 3.5186 ± 30.49 |
| 2a | Ciprofloxacin | 0.9234 ± 14.9 | 0.178 ± 0.3 | 107.63 ± 58.88 | 213.04 ± 199 | 0.0229 ± 0.007 | 2.4538 ± 3.2 | 14.123 ± 30.24 | 7.6741 ± 17.19 |
Alteration in the transcription level of the virulence genes was analyzed in infected HT-29 cells with S. flexneri serotypes 4a, 3a and 2a at mRNA level after treatment with sub-MIC concentrations of azithromycin (32 µg/mL) or ciprofloxacin (4 µg/mL). Fold changes are expressed as RQ values (2−ΔΔct) by comparison of transcription levels between treated vs untreated cells at same conditions. Azithromycin (32 µg/mL) and ciprofloxacin (4 µg/mL) were used for treatment based on the estimated MIC values for each strain. All the assays were done in duplicate and results shown are the mean ± std of two independent experiments
VirB, virulence factor production (vir) B; IpaB, invasion plasmid antigen (ipa) B; IcsA intracellular movement (ics) A, IcsB intracellular movement (ics) B gene